open access

Vol 54, No 3 (2020)
Response to Letter to the Editors
Submitted: 2020-06-09
Accepted: 2020-06-10
Published online: 2020-06-25
Get Citation

Response to “Does amantadine have a protective effect against COVID-19?”

Philip W. Tipton1, Zbigniew K. Wszolek1
·
Pubmed: 32583401
·
Neurol Neurochir Pol 2020;54(3):286-287.
Affiliations
  1. Department of Neurology, Mayo Clinic Florida, Jacksonville, United States

open access

Vol 54, No 3 (2020)
Responses to Letter to the Editors
Submitted: 2020-06-09
Accepted: 2020-06-10
Published online: 2020-06-25

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

COVID-19, amantadine, memantine, Parkinson’s disease

About this article
Title

Response to “Does amantadine have a protective effect against COVID-19?”

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 54, No 3 (2020)

Article type

Response to Letter to the Editors

Pages

286-287

Published online

2020-06-25

Page views

5191

Article views/downloads

5260

DOI

10.5603/PJNNS.a2020.0048

Pubmed

32583401

Bibliographic record

Neurol Neurochir Pol 2020;54(3):286-287.

Keywords

COVID-19
amantadine
memantine
Parkinson’s disease

Authors

Philip W. Tipton
Zbigniew K. Wszolek

References (9)
  1. Lippi A, Domingues R, Setz C, et al. SARS-CoV-2: At the Crossroad Between Aging and Neurodegeneration. Mov Disord. 2020; 35(5): 716–720.
  2. Richardson S, Hirsch JS, Narasimhan M, et al. and the Northwell COVID-19 Research Consortium. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020 [Epub ahead of print].
  3. Reeve A, Simcox E, Turnbull D. Ageing and Parkinson's disease: why is advancing age the biggest risk factor? Ageing Res Rev. 2014; 14: 19–30.
  4. Tipton PW, Wszolek ZK. What can Parkinson's disease teach us about COVID-19? Neurol Neurochir Pol. 2020; 54(2): 204–206.
  5. Brison E, Jacomy H, Desforges M, et al. Novel treatment with neuroprotective and antiviral properties against a neuroinvasive human respiratory virus. J Virol. 2014; 88(3): 1548–1563.
  6. Cortés Borra A. Does amantadine have a protective effect against COVID-19? Neurol Neurochir Pol. 2020 [Epub ahead of print].
  7. Fasano A, Cereda E, Barichella M, et al. COVID-19 in Parkinson's Disease Patients Living in Lombardy, Italy. Mov Disord. 2020 [Epub ahead of print].
  8. Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Mult Scler Relat Disord. 2020 [Epub ahead of print]; 42: 102163.
  9. Arons MM, Hatfield KM, Reddy SC, et al. Public Health–Seattle and King County and CDC COVID-19 Investigation Team. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. N Engl J Med. 2020; 382(22): 2081–2090.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl